The Unciti-Broceta Group is based at the Cancer Research UK Edinburgh Centre, part of the Institute of Genetics and Cancer at the University of Edinburgh, where Prof Unciti-Broceta established the chemistry section of the Institute in 2010.
The lab explores novel chemical strategies to improve the efficacy and safety of cancer treatments. This includes the discovery and development of anticancer kinase inhibitors and prodrugs that are activated by bioorthogonal reactions.
JUL 2022 See Shiao's work on a new way to target and kill cancer cells just published in JACS Au.
MAY 2022 WELCOME TO NEW LAB MEMBER! Saul will work in a joint project with Nuvectis Pharma to progress the preclinical development of our SRC inhibitor eCF506 (now NXP900).
FEB 2022 See our last contribution to understanding the potential of eCF506 in breast cancer just published in Cancer Research. Work led by Henry Beetham and Val Brunton.
JAN 2022 See our last work published in the first issue of 2022 in Journal of Medicinal Chemistry. After years of research, we show Pd-triggered local chemotherapy works in vivo and can solve inherent DMPK issues of a chemotherapy drug such as 5FU. A key milestone in the history of our lab!
NOV 2021 CONGRATULATIONS TO DR DAN BAILLACHE!! He successfully passed his viva with minor revision
NOV 2021 Check out our new biomedical application of bioorthogonal catalysis just published in Angewandte Chemie.
OCT 2021 Interested in the chemistry behind approved kinase inhibitors? Check out our comprehensive perspective in Journal of Medicinal Chemistry.
SEP 2021 NXP900 (aka eCF506), discovered by our lab, a selective inhibitor of SRC and YES1, is licensed to Nuvectis Pharma.
AUG 2021 10 years of research culminates with this work, published in Cancer Research. Our most important contribution to the cancer field. Joint effort from @EdinCRC, @MRC_CRH and @CIB_CSIC!!